Get the Stockscreener App
1.50
0.00%
0.00
After Hours:
1.50
Zenvia Inc stock is traded at $1.50, with a volume of 1,365.
It is up +0.00% in the last 24 hours and down -20.21% over the past month.
Zenvia Inc provides a platform that enables companies to create unique journeys for their end customers across a variety of channels. The company operates in two reportable segments namely CPaaS and SaaS. It has a geographic presence in Brazil, the USA, Argentina, Mexico, and Others. The company generates the majority of its revenue from Brazil.
See More
Previous Close:
$1.50
Open:
$1.52
24h Volume:
1,365
Relative Volume:
0.03
Market Cap:
$76.10M
Revenue:
$151.37M
Net Income/Loss:
$-36.78M
P/E Ratio:
-1.5687
EPS:
-0.9562
Net Cash Flow:
$25.70M
1W Performance:
+5.63%
1M Performance:
-20.21%
6M Performance:
-30.23%
1Y Performance:
+38.89%
1-Day Range:
$1.471
$1.52
1-Week Range:
$1.345
$1.58
52-Week Range:
$0.80
$3.8799
Zenvia Inc Stock (ZENV) Company Profile
Zenvia Inc Stock (ZENV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-21-22 | Downgrade | Itau BBA | Outperform → Market Perform |
| Aug-23-21 | Initiated | Itau BBA | Outperform |
| Aug-16-21 | Initiated | Goldman | Buy |
Zenvia Inc Stock (ZENV) Latest News
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Zenas BioPharma sees $15 million in stock purchases by Zebra Aggregator - Investing.com Canada
Is this affordable and accessible eyewear brand worth the hype? - Reviewed
Wedbush lifts Zentalis Pharmaceuticals Inc [ZNTL] price estimate. Who else is bullish? - The DBT News
Trading Day Review: Zevra Therapeutics Inc (ZVRA) Loses Momentum, Closing at 7.53 - The Dwinnex
Adversity is less terrifying than hope: Zentalis Pharmaceuticals Inc (ZNTL) - SETE News
You might want to take a look at Zevra Therapeutics Inc (ZVRA) now - SETE News
Potential Price Increase for Zentalis Pharmaceuticals Inc (ZNTL) After Recent Insider Activity - Knox Daily
Daily Market Movement: Zentalis Pharmaceuticals Inc (ZNTL) Sees a 11.41 Increase, Closing at 4.10 - The Dwinnex
Zenith UK appoints Sannah Rogers chief executive - CampaignLive
Zendaya's baby pics that show she's always been that girl - Hindustan Times
Zenas BioPharma director acquires $999k in company stock By Investing.com - Investing.com Canada
FDA lifts partial clinical hold on Zentalis Pharma’s cancer WEE1 inhibitor - Pharmaceutical Technology
Zevra Therapeutics Inc (ZVRA)’s stock decline to 7.78 per share - US Post News
Zentalis Stock Up as FDA Lifts Partial Hold on Cancer Drug Studies - Zacks Investment Research
Zeneara Reviews"HYPE-LEGIT" HAPPY Customer or Controversy? - openPR
IPO Radar: Applied Nutrition, Zenas BioPharma, BingEx - The Armchair Trader
Zenith Bank Rises Slightly after ‘Fund’ Amass Huge Shares - MarketForces Africa
Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm - PR Newswire
Zenas BioPharma director buys $7.48m in company stock By Investing.com - Investing.com South Africa
Fairmount Healthcare Fund II L.P. buys $5.1m of Zenas BioPharma stock By Investing.com - Investing.com South Africa
SR One Capital management buys $38m of Zenas BioPharma stock - Investing.com
Understanding the Risks of Investing in Zevra Therapeutics Inc (ZVRA) - Knox Daily
Zentalis Pharmaceuticals Inc’s Banking’s 100-Day Moving Average at 6.58: Will the Stock Break Through? - The InvestChronicle
Zentalis clinical hold resolution came ‘no strings attached,’ says Oppenheimer - TipRanks
Zentalis Pharma gains as FDA lifts partial clinical hold on cancer drug studies - XM
Zentalis Shares Rise After U.S. FDA Lifts Hold on Azenosertib Studies - MarketWatch
Zentalis Pharmaceuticals Advances with FDA Approval and Upcoming Data - TipRanks
Zenas Biopharma IPO raises $225 mln in US IPO market - Eyes On News
Zenas BioPharma shares rise nearly 8% in market debut - XM
Zenas BioPharma raises $225 mln in US IPO - Reuters
Zenas BioPharma Announces Pricing of Upsized Initial Public Offering - GlobeNewswire
Zenvia Inc. (NASDAQ:ZENV) Q2 2024 Earnings Call Transcript - MSN
Zenvia Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Simply Wall St
Zenvia Inc. (NASDAQ:ZENV) Q2 2024 Earnings Call Transcript - Insider Monkey
Earnings call: Zenvia reports robust Q2 2024 growth, plans expansion By Investing.com - Investing.com Canada
Zenvia Inc. Complies with SEC’s September Filing - TipRanks
Zenvia Inc. Reports Mid-Year Financial Performance - TipRanks
Zenvia Inc. Soars with Robust Q2 2024 Earnings - TipRanks
Zenvia Reports Revenue and Profit Growth - TipRanks
Zenvia (NASDAQ:ZENV) Announces Quarterly Earnings Results - MarketBeat
Zenvia Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Zenvia reports Q2 revenue BRL 231.2M vs. BRL 192.9M last year - TipRanks
ZENVIA Reports Q2 2024 and H1 2024 Results - StockTitan
Earnings To Watch: Zenvia Inc (ZENV) Reports Q2 2024 Result - GuruFocus.com
Zenvia Inc (ZENV) Q2 2024 Earnings Report Preview: What To Expec - GuruFocus.com
Zenvia (ZENV) to Release Earnings on Thursday - MarketBeat
Zenvia (ZENV) Set to Announce Quarterly Earnings on Thursday - Defense World
ZENVIA sets agenda for fiscal second quarter and first half 2024 results - StockTitan
Short Interest in Zenvia Inc. (NASDAQ:ZENV) Increases By 37.9% - MarketBeat
Zenvia Inc. (NASDAQ:ZENV) Short Interest Update - Defense World
Zenvia Inc Stock (ZENV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.35%
2.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):